Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Net Cash Flow: 2017-2024

Historic Net Cash Flow for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $15.9 million.

  • Solid Biosciences' Net Cash Flow fell 36.50% to $15.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.3 million, marking a year-over-year increase of 107.55%. This contributed to the annual value of $6.3 million for FY2024, which is 107.79% up from last year.
  • As of Q4 2024, Solid Biosciences' Net Cash Flow stood at $15.9 million, which was up 150.45% from -$31.4 million recorded in Q3 2024.
  • Solid Biosciences' Net Cash Flow's 5-year high stood at $113.8 million during Q1 2021, with a 5-year trough of -$90.9 million in Q3 2021.
  • Over the past 3 years, Solid Biosciences' median Net Cash Flow value was $1.9 million (recorded in 2022), while the average stood at -$3.5 million.
  • As far as peak fluctuations go, Solid Biosciences' Net Cash Flow soared by 1,035.32% in 2022, and later tumbled by 670.37% in 2023.
  • Quarterly analysis of 5 years shows Solid Biosciences' Net Cash Flow stood at $1.2 million in 2020, then spiked by 651.24% to $9.4 million in 2021, then spiked by 1,035.32% to $106.4 million in 2022, then slumped by 76.51% to $25.0 million in 2023, then crashed by 36.50% to $15.9 million in 2024.
  • Its Net Cash Flow was $15.9 million in Q4 2024, compared to -$31.4 million in Q3 2024 and -$21.6 million in Q2 2024.